Peer-reviewed veterinary case report
Vinblastine as second treatment for dogs with multicentric lymphoma
By Lenz, J A et al.·Published in The Journal of small animal practice·2016·Department of Medical Sciences, United States·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Vinblastine as a second rescue for the treatment of canine multicentric lymphoma in 39 cases (2005 to 2014).
- Species:
- dog
Plain-English summary
A group of 39 dogs with multicentric lymphoma (a type of cancer) that had not responded to previous treatments received vinblastine as a second option. Some dogs showed improvement: 3 achieved complete remission, while 7 had a partial response, and 18 maintained stable disease. However, many experienced side effects, including low white blood cell and platelet counts. On average, dogs lived about 46 days after starting vinblastine, with some surviving longer. While vinblastine was generally tolerated, the responses were often short-lived.
People also search for: dog lymphoma treatment options · vinblastine for dogs cancer · canine cancer survival rates
Abstract
OBJECTIVES: The objective of this study was to retrospectively evaluate response and outcome of dogs with multicentric lymphoma treated with single-agent vinblastine as a second rescue. METHODS: Medical records from 39 client-owned dogs receiving vinblastine rescue treatment (having relapsed on or following completion of UW-Madison and CCNU/L-asparaginase protocols), between 2005 and 2014, were reviewed for information regarding clinical presentation, diagnostic testing, drug dosage, number of treatments, side effects, response and outcome. RESULTS: The median starting dose of vinblastine was 2·6 mg/m(2) (1·7 to 2·8 mg/m(2) ), administered weekly until disease progression. Of the 39 dogs treated, 3 dogs (7·7%) achieved a complete remission, 7 dogs (17·9%) achieved a partial response, 18 dogs (46·2%) maintained stable disease and 11 (28·2%) had progressive disease. Ten dogs (25·6%) developed a grade III or IV neutropenia, and 4 dogs (10·3%) developed grade III or IV thrombocytopenia (one dog in both categories). After starting vinblastine, the median progression-free survival was 29·5 days (0 to 77 days) and overall median survival time was 46 days (4 to 250 days). Duration of first remission was identified as a positive predictor of outcome. CLINICAL SIGNIFICANCE: Single-agent vinblastine is well tolerated in dogs with relapsed or refractory lymphoma. Responses were incomplete and short-lasting.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/27251593/